Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nutriventia Private Limited manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units and involve 3 distinct examiners. TIEN, LUCY MINYU is the busiest examiner for the company, currently handling 1 pending office action. The distribution of these matters among 3 distinct examiners indicates that no single examiner is handling multiple active cases.
The 3 distinct art units suggest a variety of technical focuses within the biotechnology field. TIEN, LUCY MINYU is responsible for 1 pending office action, which is the same volume as the other examiners involved in the portfolio. This 3 to 3 ratio of pending office actions to distinct examiners indicates a decentralized prosecution experience. Practitioners can expect to interact with 3 distinct art units, reflecting the technical classifications of the matters currently under review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIEN, LUCY MINYU | 1 | 59.1% | +36.8% |
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
| SILVERMAN, JANICE Y | 1 | 37.6% | +53.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257160 | STABLE PROLONGED RELEASE FORMULATION OF VITAMIN C AND A PROCESS FOR PREPARATION THEREOF | TIEN, LUCY MINYU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250782 | MODIFIED RELEASE COMPOSITIONS COMPRISING MELATONIN | JOSEPH, JANET | 21d |
| 18257160 | STABLE PROLONGED RELEASE FORMULATION OF VITAMIN C AND A PROCESS FOR PREPARATION THEREOF | TIEN, LUCY MINYU | — |
| 18002440 | PROLONGED RELEASE FORMULATION OF CAFFEINE | SILVERMAN, JANICE Y | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1611 | 1 |
| 1792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257160 | STABLE PROLONGED RELEASE FORMULATION OF VITAMIN C AND A PROCESS FOR PREPARATION THEREOF | TIEN, LUCY MINYU | 1612 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18250782 | MODIFIED RELEASE COMPOSITIONS COMPRISING MELATONIN | JOSEPH, JANET | 1611 | §103 | Final Rejection | 21d | Pending | Apr 27, 2023 |
| 18002440 | PROLONGED RELEASE FORMULATION OF CAFFEINE | SILVERMAN, JANICE Y | 1792 | §103 | Final Rejection | — | Pending | Dec 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNutriventia Private Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Lucy Minyu Tien has the most, with 1 of Nutriventia Private Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
